Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 1/20 | 0.56 |
| ▸ | ZDHHC20 | Q5W0Z9 | 2/20 | 0.44 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 13/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3255350 | 0.80 | ALDH1A1 (0.38) | CASP1ZDHHC20ZDHHC2ALDH1A1 | |
| SCHEMBL2654972 | 0.80 | CASP1 (0.56) | CASP1ALDH1A1MAPTHPGDHTT | |
| SCHEMBL3405331 | 0.79 | — | — | |
| SCHEMBL2478566 | 0.79 | ZDHHC20 (0.50) | CASP1ZDHHC20ZDHHC2ALDH1A1MAPT | |
| SCHEMBL1864608 | 0.77 | ZDHHC20 (0.53) | CASP1ZDHHC20ZDHHC2ALDH1A1HPGD | |
| SCHEMBL6631976 | 0.77 | — | — | |
| SCHEMBL16776767 | 0.76 | ZDHHC20 (0.42) | CASP1ZDHHC20ZDHHC2ALDH1A1HPGD | |
| SCHEMBL14341773 | 0.76 | ZDHHC20 (0.38) | CASP1ZDHHC20ZDHHC2ALDH1A1HPGD | |
| SCHEMBL27402656 | 0.76 | ZDHHC20 (0.41) | CASP1ZDHHC20ZDHHC2ALDH1A1HPGD | |
| SCHEMBL21846296 | 0.74 | CASP1 (0.58) | CASP1ALDH1A1MAPTHPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023090304-A1 | POLYMER, ELASTOMER, PRODUCTION METHOD THEREFOR, ACTUATOR, AND SENSOR | 大阪有機化学工業株式会社 | 2023-05-25 | — | — | WO | disclosed |
| US-7700638-B2 | 1,5,7-trisubstituted benzimidazole derivatives and their use for modulating the GABAA receptor complex | N. V. ORGANON (NL) | 2010-04-20 | — | — | US | disclosed |
| US-7670737-B2 | UV absorbing hole blocking layer containing photoconductors | XEROX CORPORATION (US) | 2010-03-02 | — | — | US | disclosed |
| US-20090035674-A1 | UV ABSORBING HOLE BLOCKING LAYER CONTAINING PHOTOCONDUCTORS | XEROX CORPORATION (US) | 2009-02-05 | — | — | US | disclosed |
| US-20070021482-A1 | 1,5,7-Trisubstituted benzimidazole derivatives and their use for modulating the gabaa receptor complex | N.V. ORGANON (NL) | 2007-01-25 | — | — | US | disclosed |
| EP-1678144-A1 | 1,5,7-TRISUBSTITUTED BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABA-a RECEPTOR COMPLEX | Akzo Nobel N.V. (NL) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005040131-A1 | 1,5,7-TRISUBSTITUTED BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | AKZO NOBEL N.V. (NL) | 2005-05-06 | — | — | WO | disclosed |
| US-6605270-B1 | Removing iron from patient by orally administering therapeutically effective amount of polymer characterized by specified repeat unit, or heteropolymer thereof | GENZYME CORPORATION | 2003-08-12 | — | — | US | disclosed |
| EP-0699072-B1 | USE OF IRON-BINDING POLYMERS FOR THE MANUFACTURE OF A MEDICAMENT FOR ORAL ADMINISTRATION | GELTEX PHARMA INC (US) | 2003-04-23 | — | — | EP | disclosed |
| US-5702696-A | FOR TREATMENT OF IRON OVERLOAD DISORDERS | GELTEX PHARMACEUTICALS (US) | 1997-12-30 | — | — | US | disclosed |
| US-5487888-A | Iron-binding polymers for oral administration | GELTEX, INC. (US) | 1996-01-30 | — | — | US | disclosed |
| WO-1994027621-A1 | IRON-BINDING POLYMERS FOR ORAL ADMINISTRATION | GELTEX, INC. (US) | 1994-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021482-A1 | 1,5,7-Trisubstituted benzimidazole derivatives and their use for modulating the gabaa receptor complex | GABRB1, GABRA5, GABRB2 | CASP1 3020/4885ZDHHC20 2812/4885ZDHHC2 2950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.